34.8EGP
- Active ingredient
- strontium ranelate
- Form
- sachet
- Manufacturer
- bioriginal international group pharma egypt > arabian international group (aig)
- Route
- eff
Uses
Used for the treatment of severe osteoporosis in selected patients at high risk of fracture.
Do not use if
Contraindicated in patients with current or previous venous thromboembolism and certain cardiovascular conditions.
Side effects
Nausea, diarrhea, headache, and skin reactions may occur.
Warnings
Cardiovascular risk should be assessed before and during treatment.
How it works
Acts on bone metabolism by promoting bone formation and reducing bone resorption.
Storage
Store at room temperature protected from moisture.